Last reviewed · How we verify
ABT-348 and carboplatin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ABT-348 and carboplatin (ABT-348 and carboplatin) — AbbVie (prior sponsor, Abbott).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ABT-348 and carboplatin TARGET | ABT-348 and carboplatin | AbbVie (prior sponsor, Abbott) | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ABT-348 and carboplatin CI watch — RSS
- ABT-348 and carboplatin CI watch — Atom
- ABT-348 and carboplatin CI watch — JSON
- ABT-348 and carboplatin alone — RSS
Cite this brief
Drug Landscape (2026). ABT-348 and carboplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-348-and-carboplatin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab